{"id":"NCT00970268","sponsor":"AstraZeneca","briefTitle":"Long-term Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-36)","officialTitle":"A Long-term, Randomized, Double-blind Extension Study of the Safety, Tolerability, and Efficacy of Aclidinium Bromide at Two Dose Levels When Administered to Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-08","primaryCompletion":"2010-10","completion":"2010-10","firstPosted":"2009-09-02","resultsPosted":"2012-09-14","lastUpdate":"2017-01-06"},"enrollment":291,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease"],"interventions":[{"type":"DRUG","name":"Aclidinium bromide","otherNames":[]},{"type":"DRUG","name":"Aclidinium bromide","otherNames":[]}],"arms":[{"label":"1","type":"EXPERIMENTAL"},{"label":"2","type":"EXPERIMENTAL"}],"summary":"The purpose of this extension study is to evaluate the long-term safety, tolerability, and efficacy of inhaled aclidinium bromide at two dose levels in patients with moderate to severe chronic obstructive pulmonary disease (COPD). This study will be 54 weeks in duration; a 52-week double-blind treatment period and 2 week follow-up phone call, following a 12 week lead-in study. All patients will be randomized from the lead-in study at one of two doses of aclidinium.","primaryOutcome":{"measure":"Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)","timeFrame":"Change from baseline (visit 2 of lead-in study LAS-MD-33) to 52 weeks","effectByArm":[{"arm":"Placebo - Aclidinium Bromide 200 μg","deltaMin":-0.035,"sd":0.04},{"arm":"Aclidinium Bromide 200 μg - Aclidinium Bromide 200 μg","deltaMin":0.069,"sd":0.028},{"arm":"Placebo - Aclidinium Bromide 400 μg","deltaMin":0.069,"sd":0.037},{"arm":"Aclidinium Bromide 400 μg - Aclidinium Bromide 400 μg","deltaMin":0.056,"sd":0.025}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":8},"locations":{"siteCount":83,"countries":["United States","Canada"]},"refs":{"pmids":["23679347"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":44},"commonTop":["Chronic obstructive pulmonary disorder","Nasopharyngitis","Urinary tract infection","Upper respiratory tract infection","Cough"]}}